Roivant Sciences (ROIV) Gross Margin (2020 - 2025)
Roivant Sciences (ROIV) reported Gross Margin of 64.98% for Q4 2025, down 3215.0% on a YoY basis from 2.09% in Q4 2024, and down 30.08% quarter-over-quarter from 92.93% in Q3 2025.
Roivant Sciences (ROIV) Gross Margin (2020 - 2025) Analysis & Trends
Roivant Sciences has reported Gross Margin for 6 years, with the latest figure at 64.98% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin fell 3215.0% year-over-year to 64.98%; the trailing twelve-month figure through Dec 2025 stood at 91.71% (down 586.0% YoY), and the FY2026 full-year result was 84.44%, down 1242.0% from the prior year.
- Gross Margin for Q4 2025 stood at 64.98%, down from 92.93% in the prior quarter.
- The five-year high for Gross Margin was 98.73% in Q4 2023, with the low at 54.38% in Q3 2021.
- Historically, Gross Margin has averaged 84.15% across 5 years, with a median of 92.9% in 2025.
- Annual changes were most pronounced in 2023 — Gross Margin jumped 2294 bps — and 2025, when it plunged 3215 bps.
- Roivant Sciences' Gross Margin stood at 94.31% in 2021, then dropped by 16 bps to 78.97% in 2022, then increased by 25 bps to 98.73% in 2023, then fell by 2 bps to 97.13% in 2024, then sank by 33 bps to 64.98% in 2025.
- The last three Gross Margin figures came in at 64.98% (Q4 2025), 92.93% (Q3 2025), and 92.9% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 64.98% |
| Sep 30, 2025 | 92.93% |
| Jun 30, 2025 | 92.90% |
| Dec 31, 2024 | 97.13% |
| Sep 30, 2024 | 94.77% |
| Jun 30, 2024 | 97.33% |
| Dec 31, 2023 | 98.73% |
| Sep 30, 2023 | 93.89% |
| Jun 30, 2023 | 80.51% |
| Dec 31, 2022 | 78.97% |
| Sep 30, 2022 | 70.95% |
| Jun 30, 2022 | 60.04% |
| Dec 31, 2021 | 94.31% |
| Sep 30, 2021 | 54.38% |
| Jun 30, 2021 | 90.41% |
| Dec 31, 2020 | 88.10% |
| Sep 30, 2020 | 45.96% |
| Jun 30, 2020 | 88.58% |